Pure Global AI
NCT06299371Not yet recruiting

Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations

A Prospective, Single-arm Study of Adebrelimab in Combination With Paclitaxel for Injection (Albumin Bound) and Platinum Chemotherapy as Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) Harboring Driver Gene Mutations
Liaoning Tumor Hospital & InstitutePhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Non Small Cell Lung Cancer
Drug/Device/Intervention
Adebrelimab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Liaoning Tumor Hospital & Institute
Timeline & enrollment
Phase
Phase 2
Start date
Apr 15, 2024
End date
Apr 15, 2029
Enrollment
36 participants
Primary outcome

Pathological complete response rate

Summary

This is a prospective, single-arm study to investigate the efficacy and safety of Adebrelimab
 in combination with paclitaxel for injection (albumin bound) and platinum chemotherapy as
 neoadjuvant therapy in resectable non-small cell lung cancer harboring driver gene mutations

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06299371
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06299371 through Pure Global AI's free database. This Phase 2 trial is sponsored by Liaoning Tumor Hospital & Institute and is currently Not yet recruiting. The study focuses on Non Small Cell Lung Cancer. Target enrollment is 36 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.